Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
about
Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approachesEngineering anti-GD2 monoclonal antibodies for cancer immunotherapy.GD2-targeted immunotherapy and radioimmunotherapyPosterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodyniaNeuroblastoma: developmental biology, cancer genomics and immunotherapy.Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.Immunotherapy targets in pediatric cancer.Introduction to monoclonal antibodies.Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.Development of treatment strategies for advanced neuroblastoma.Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.Glycans as targets for therapeutic antitumor antibodies.Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis.More than the genes, the tumor microenvironment in neuroblastoma.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3.Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.Anti-GD2 immunotherapy for neuroblastoma.ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer.Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.CAR T Cell Therapy for Neuroblastoma
P2860
Q21129299-85819A3B-9D9E-464C-A665-01B2EF676D70Q34389202-029E3AE3-1320-42E8-89B4-BED1E49590DCQ34625339-BBF52C7C-BA2D-4DC4-AAEA-D42A3F1794C4Q35077759-5C224F96-A88E-42C1-AB10-B57C948F1D05Q35092616-1998559A-C8EC-4FF7-84E9-0C1FE68366FCQ35283020-BDAF71D6-2204-48B8-A160-465D0998D6DBQ35587509-017C31FF-7AEF-489A-88AD-5FFC8A226707Q35971029-A2A6DB07-8160-48DE-8D29-181FE89601D5Q36050008-9FE7A74D-F74A-4FD1-AA3F-CB1531208124Q36665174-15B714E4-BDDD-4F1B-ABE1-7E5BC508CF6DQ37592957-3A4D5910-1EAE-49B4-AC28-7ADC335B1D30Q38010377-B7A61509-EAF8-467A-A918-9D7D62898108Q38014527-F5EA8905-E011-452D-83FA-BA4E1357580FQ38034815-935A595A-064F-47E9-A2E2-2FCE623E68A8Q38079519-A73AE278-9172-452C-9FE1-F76C6EE7FD53Q38352205-CB2464FF-138C-493E-B374-6FB875284336Q38644731-EF34895C-07A7-40D1-AA61-3C08C93B7FC8Q38961012-BCB7C024-0DCA-4DD9-8E7A-3C8C2DA4F3B2Q39342110-1E0DB620-8C6A-4707-B0B0-67C5DC088C9BQ40700335-60593936-5720-4B5A-B9DC-0570FD6026B5Q41613624-DE366DD3-2147-49DD-ADE0-C46599BB4639Q42053371-0E04C928-36FD-475D-A946-305B06EB2432Q47170529-E61BAFE0-C4BD-4046-AD20-D7396701CB4FQ47554435-0AAD8560-C55A-4466-AB5E-7B24F3370861Q48277237-970413A8-18CA-4AD4-8345-343D73335B02Q55216432-67628C64-E020-4326-9848-CA96DC9AAE86Q55501991-54B74400-37FD-49B2-A90F-1ECD14D034A6Q59127901-50B0851E-3834-484E-A506-2E942FF37F11
P2860
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Successful multifold dose esca ...... euroblastoma: a phase I study.
@ast
Successful multifold dose esca ...... euroblastoma: a phase I study.
@en
Successful multifold dose esca ...... euroblastoma: a phase I study.
@nl
type
label
Successful multifold dose esca ...... euroblastoma: a phase I study.
@ast
Successful multifold dose esca ...... euroblastoma: a phase I study.
@en
Successful multifold dose esca ...... euroblastoma: a phase I study.
@nl
prefLabel
Successful multifold dose esca ...... euroblastoma: a phase I study.
@ast
Successful multifold dose esca ...... euroblastoma: a phase I study.
@en
Successful multifold dose esca ...... euroblastoma: a phase I study.
@nl
P2093
P2860
P356
P1476
Successful multifold dose esca ...... neuroblastoma: a phase I study
@en
P2093
Brian H Kushner
Kim Kramer
Nai-Kong V Cheung
P2860
P304
P356
10.1200/JCO.2010.28.3317
P407
P577
2011-02-22T00:00:00Z